Evidence map›Paper›PMID 34504302›Full record

ArticleThe pharmacogenomics journal2022

Polymorphisms at CYP enzymes, NR1I2 and NR1I3 in association with virologic response to antiretroviral therapy in Brazilian HIV-positive individuals.

Camila de Almeida Velozo, Tailah Bernardo de Almeida, Marcelo Costa Velho Mendes de Azevedo, Isabela Espasandin, Jorge Francisco da Cunha Pinto, Sheila López, Luciana Pizzatti, Amilcar Tanuri, Sabrina da Silva Santos, Marcelo Ribeiro-Alves and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in The pharmacogenomics journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Roles ofFrontiers in genetics · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Camila de Almeida VelozoLaboratório de Virologia Molecular, Departamento de Genética, Instituto de Biologia, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.ORCID http://orcid.org/0000-0003-0105-1312
Tailah Bernardo de AlmeidaLaboratório de Virologia Molecular, Departamento de Genética, Instituto de Biologia, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.
Marcelo Costa Velho Mendes de AzevedoHospital Universitário Gaffrée e Guinle, Universidade Federal do Estado do Rio de Janeiro (UNIRIO), Rio de Janeiro, Brazil.
Isabela EspasandinLaboratório de Virologia Molecular, Departamento de Genética, Instituto de Biologia, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.
Jorge Francisco da Cunha PintoHospital Universitário Gaffrée e Guinle, Universidade Federal do Estado do Rio de Janeiro (UNIRIO), Rio de Janeiro, Brazil.
Sheila LópezLaboratório de Biologia Molecular e Proteômica do Sangue - Instituto de Química/LADETEC, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.
Luciana PizzattiLaboratório de Biologia Molecular e Proteômica do Sangue - Instituto de Química/LADETEC, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.
Amilcar TanuriLaboratório de Virologia Molecular, Departamento de Genética, Instituto de Biologia, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.
Sabrina da Silva SantosEscola Nacional de Saúde Pública Sérgio Arouca, FIOCRUZ, Rio de Janeiro, Brazil.ORCID http://orcid.org/0000-0001-8327-3546
Marcelo Ribeiro-AlvesInstituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro, Brazil.
Cynthia Chester CardosoLaboratório de Virologia Molecular, Departamento de Genética, Instituto de Biologia, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil. cynthiac@biologia.ufrj.br.ORCID http://orcid.org/0000-0003-0565-7047
Universidade Federal do Rio de Janeiro · BRHospital Universitário Gaffrée e Guinle · BREscola Nacional de Saúde Pública · BRInstituto Evandro Chagas · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Virologic failure of antiretroviral therapy (ART) may be explained by single nucleotide polymorphisms (SNPs) in drug absorption and metabolism genes. Here, we characterized the associations between polymorphisms in cytochrome P450 enzymes' genes CYP2B6 and CYP3A4/A5, nuclear receptor genes NR1I2/3, and initial ART efficacy among 203 HIV-positive individuals from Rio de Janeiro. Association between SNPs and virologic control was evaluated after 6 and 12 months of follow-up using Cox regression models. The SNP rs2307424 (NR1I3) was associated with increased virologic response after 12 months of treatment, while rs1523127 (NR1I2), rs3003596, and rs2502815 (NR1I3) were associated with decreased response. Increased virologic response after 12 months (

Indexed as

AdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBrazilCohort StudiesConstitutive Androstane ReceptorCytochrome P-450 CYP2D6Cytochrome P-450 CYP3ACytochrome P-450 Enzyme SystemFemaleHaplotypesHIV InfectionsHIV SeropositivityHumansMaleMiddle AgedAnti-HIV AgentsConstitutive Androstane ReceptorCYP3A4 protein, humanCYP3A5 protein, humanCytochrome P-450 CYP2D6Cytochrome P-450 CYP3ACytochrome P-450 Enzyme SystemNR1I2 protein, humanNR1I3 protein, humanNR1 NMDA receptorPregnane X ReceptorReceptors, N-Methyl-D-Aspartate

Identifiers

PMID34504302
OpenAlexW3198171897

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.